China Nuokang Bio-Pharma, a leading provider of blood-clotting medication in China, will see its quiet period end next Monday, Jan. 18. On Dec. 9, 2009, the company raised $45 million by offering 5 million shares at $9 each, below the range of $10-$12. ...read more
Eight deals were originally slated to begin trading this week in what would have been, if all had priced, the busiest IPO week of the year. However, only four of the eight ultimately made it to market, reflecting subdued deal demand and investors' lingering...read more
China Nuokang Bio-Pharma, a leading provider of blood-clotting medication in China, raised $45 million by offering 5 million ADSs at $9.00, below the low end of the $10.00 to $12.00 proposed range. China Nuokang Bio-Pharma is expected to begin trading Thursday...read more
This week, three profitable Chinese companies will attempt to take advantage of the recent interest and confidence investors have shown in the IPO markets: a solar module provider, a cancer center operator and a biopharmaceutical company will all come to market...read more
China Nuokang quiet period ends January 18
China Nuokang Bio-Pharma, a leading provider of blood-clotting medication in China, will see its quiet period end next Monday, Jan. 18. On Dec. 9, 2009, the company raised $45 million by offering 5 million shares at $9 each, below the range of $10-$12. ...read more
Four of eight planned IPOs this week complete deals
Eight deals were originally slated to begin trading this week in what would have been, if all had priced, the busiest IPO week of the year. However, only four of the eight ultimately made it to market, reflecting subdued deal demand and investors' lingering...read more
China Nuokang prices IPO at $9.00, below the range
China Nuokang Bio-Pharma, a leading provider of blood-clotting medication in China, raised $45 million by offering 5 million ADSs at $9.00, below the low end of the $10.00 to $12.00 proposed range. China Nuokang Bio-Pharma is expected to begin trading Thursday...read more
Three Chinese IPOs expected to debut this week
This week, three profitable Chinese companies will attempt to take advantage of the recent interest and confidence investors have shown in the IPO markets: a solar module provider, a cancer center operator and a biopharmaceutical company will all come to market...read more